Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy

NCT02072408

Polypoidal Choroidal Vasculopathy Without Active Polyp

COMPLETED PHASE4

Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy

NCT00383812

Polypoidal Choroidal Vasculopathy

UNKNOWN NA

Real Life Study in Myopic Neovascularization

NCT03797547

Myopic Choroidal Neovascularisation

UNKNOWN

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

NCT01012973

Retinal Vein Occlusion

COMPLETED PHASE3

Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)

NCT02860858

Symtomatic Macular Polypoidal Choroidal Vasculopathy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Efficacy of VEGF Trap-Eye (aflibercept, Eylea) for exudative age-related macular degeneration (AMD) was demonstrated in the phase III VIEW study. Polypoidal choroidal vasculopathy (PCV) is considered as a subtype of exudative AMD, however it is reportedly different from choroidal new vessels based on the histologic studies. The aim of this study is to evaluate effects of VEGF Trap-Eye in treatment of PCV, which was diagnosed using indocyanine green (ICG) angiography. VEGF Trap-Eye will be injected intravitreally bimonthly after 3 monthly loading dose for 12 months in treatment-naive PCV patients. The efficacy will be evaluated on preserving visual acuity and improving angiographic features at 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Exudative Age-related Macular Degeneration Polypoidal Choroidal Vasculopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

aflibercept

Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year).

Group Type EXPERIMENTAL

aflibercept

Intervention Type DRUG

Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aflibercept

Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Eyelea, VEGF Trap-Eye

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Submacular PCV diagnosed using ICG angiography with no previous treatment (branching vascular network with or without polypoidal dilation in ICG angiography)
* Presence of signs of recent activity of PCV

1. Visual acuity between 20/40 and 20/320
2. Active leakage in fluorescein angiography
3. Presence of any fluid in OCT(optical coherence tomography)-intraretinal, subretinal, sub-retinal pigment epithelial

Exclusion Criteria

1. Extramacular PCV
2. Subretinal hemorrhage or other retinal lesions blocking angiographic characteristics in more than 50% area of PCV lesion.
3. Previous treatment of intravitreal injections (anti-VEGF, steroid or other agents)
4. Previous treatment of photodynamic therapy
5. Previous ocular surgery except cataract surgery before 3 or more months
6. Presence of exudative AMD in the other eyes requiring anti-VEGF treatment (Intravitreal bevacizumab was reported to affect the other eye.)
7. Presence of other ocular diseases which may affect visual acuity (glaucoma, cataract with opacity involving visual axis, etc)
8. Presence of uncontrolled systemic disease (diabetes mellitus, hypertension, ischemic heart disease, cerebral infarction, etc)
9. Patients who cannot understand or conform to the study protocol.
10. Patients who refuse to agree to the informed consent.
11. Patients with contraindication to aflibercept

* Ocular or periocular infection
* Active severe intraocular inflammation
* Known hypersensitivity to aflibercept or to any of the excipients

Eligible Sex

ALL

Accepts Healthy Volunteers

No